Pharma Co.'s $4.8M Investor Deal OK'd, But Fees Undecided
A California federal judge on Thursday preliminarily granted a $4.8 million proposed settlement to resolve allegations that Orexigen Therapeutics had a duty to warn investors after learning a drug wasn't as...To view the full article, register now.
Already a subscriber? Click here to view full article